The Breast Cancer Cure Blueprint 2012 Report Card.

Hybrid Pharmaceutical, the Genomics Biotech Engineering company, CEO Rose Conrad Ph.D. gives us
The Breast Cancer Cure Blueprint 2012 Report Card. From MD Anderson Galveston TX, Campus Business Wire

Hybrid GenNxeix Breast Cancer Researchers and Scientist are ahead of the curve with several new technologies based on Nanoparticles and Semi Conductors Namely Genomics and treatments.
The field of genomics is caught in a data deluge. Targeted breast cancer DNA sequencing is becoming faster and cheaper at a pace far outstripping Moore’s law, which describes the rate at which computing gets faster and cheaper.


The result is that the ability to determine Targeted breast cancer DNA sequences is starting to outrun the ability of researchers to store, transmit and especially to analyze the data.

The cost of sequencing a human genome — all three billion bases of DNA in a set of human chromosomes — plunged to $10,000.00 which means genomics breast cancer DNA sequencing is around $3000.00.
The lower cost, along with increasing speed, has led to a huge increase in how much breast Cancer sequencing data is being produced.

Numerous investigations have shown that both tissue and cell distribution profiles of anticancer drugs can be controlled by their entrapment in submicronic colloidal systems (nanoparticles). The rationale behind this approach is to increase antitumor efficacy, while reducing systemic side-effects. This review provides an update of tumor targeting with conventional or long-circulating nanoparticles. The in vivo fate of these systems, after intravascular or tumoral administration, is discussed, as well as the mechanism involved in tumor regression. Nanoparticles are also of benefit for the selective delivery of oligonucleotides to tumor cells. Moreover, certain types of nanoparticles showed some interesting capacity to reverse MDR resistance, which is a major problem in chemotherapy. The first experiments, aiming to decorate nanoparticles with molecular ligand for active targeting of cancerous cells

Miniaturization will allow the tools for many different tests to be situated together on the same small device. Hybrid GenNxeix Researchers Say that nanotechnology will allow them to run many diagnostic tests simultaneously.

Nanoparticles nanoshells is use to antibodies that recognize cancer cells. GenNxeix scientist envision letting these nanoshells seek out their cancerous targets, then applying near-infrared light. The heat generated by the light-absorbing nanoshells can successfully killed breast cancer tumor cells while leaving neighboring cells intact.

A nanometer is a billionth of a meter. It's difficult to imagine anything so small, but think of something only 1/80,000 the width of a human hair. Ten hydrogen atoms could be laid side-by-side in a single nanometer.
GenNxeix minuscule molecule that will be used to detect breast cancer is a quantum dot. Quantum dots are tiny crystals that glow when they are stimulated by ultraviolet light. The wavelength, or color, of the light depends on the size of the crystal. Latex beads filled with these crystals can be designed to bind to specific DNA sequences.
Hybrid GenNxeix understands that Hyperthermia gold nanoshell Targeted breast cancer genomics at 40 for high risk women will reduce breast cancer at 60 years of Age. Training Genomics Counselor and Storing DNA Analysis in the cloud will allow Hybrid GenNxeix to say that Chemotherapy will help their breast cancer outcome or if Chemotheraphy and Hyperthermia will extend their life.

Texas is Doing Great Things to Help in The Creation of a Blueprint for a Breast Cancer Cure

Houston, TX – December 01, 2011 - - (BUSINESS WIRE) ----- Hybrid Pharmaceuticals, the Genomics Biotech Engineering Company Hybrid Media Reporting From The Texas Workforce Commission Meeting Houston TX Galleria

Texas is doing great things to help in The Creation of a Blueprint for a Breast Cancer Cure. The University of Texas M.D. Anderson Cancer Center and The Texas
Workforce Commission Skills Development Fund are two Texas organizations that has the synergy to create a 100,00 Jobs according to Rose Conrad CEO of Hybrid GenNxeix when incorporating Nanoparticles and Semiconductor to the Drug Discovery Process.
Just this Week University of Texas M.D. Anderson Cancer Center is stocking up on scientists and plunging into the business of drug development, a major upgrade to areas that have lagged considerably behind the institution's clinical-care reputation.
The creation of the Institute for Applied Cancer Science, an effort aimed atconverting basic discoveries into new cancer therapies. The institute will be staffed by 28 scientists newly recruited from a similar initiative at the Harvard-affiliated Dana Farber Cancer Center. That initiative was co-founded and headed by Dr. Ronald DePinho, M.D. Anderson's new president.
"This will allow us to exploit opportunities provided by recent transformative technological and scientific advances and launch a biotech industry in Houston," said DePinho, who succeeded Dr. John Mendelsohn Sept. 1. "It should improve an appallingly low rate of success in the current cancer drug pipeline.".
The Texas Workforce Commission Skills Development Fund is Texas' premier job–training program providing training dollars for Texas businesses and workers. Administered by the Texas Workforce Commission, success is achieved through collaboration among businesses, public Community and Technical colleges, Local Workforce Development Boards and economic development partners.
For the next two fiscal years (September 1, 2011 – August 31, 2013), TWC has $48 million in Skills Development Funds to support high quality, customized job training projects across the state. Grants for a single business may be limited to $500,000.
How does it work?
A business, consortium of businesses, or trade union identifies a training need, and then partners with a public Community or Technical college to fill its specific needs. Businesses work with college partners to submit proposals, develop curricula and conduct training. The Skills Development Fund pays for the training, the college administers the grant, and businesses create new jobs and improve the skills of their current workers. How The Synergy would work:

GenNxeix scientist say photoluminescent nanoparticles will allow oncologists to discriminate between cancerous cells and healthy cells. Proteomics and bioinformatics will enable researchers to identify markers of Breast cancer susceptibility and precancerous lesions

Numerous investigations have shown that both tissue and cell distribution profiles of anticancer drugs can be controlled by their entrapment in submicronic colloidal systems (nanoparticles). The rationale behind this approach is to increase antitumor efficacy, while reducing systemic side-effects. This review provides an update of tumor targeting with conventional or long-circulating nanoparticles. The in vivo fate of these systems, after intravascular or tumoral administration, is discussed, as well as the mechanism involved in tumor regression. Nanoparticles are also of benefit for the selective delivery of oligonucleotides to tumor cells. Moreover, certain types of nanoparticles showed some interesting capacity to reverse MDR resistance, which is a major problem in chemotherapy. The first experiments, aiming to decorate nanoparticles with molecular ligand for active targeting of cancerous cells

Miniaturization will allow the tools for many different tests to be situated together on the same small device. Researchers hope that nanotechnology will allow them to run many diagnostic tests simultaneously.

Nanoparticles nanoshells is use to antibodies that recognize cancer cells. GenNxeix scientist envision letting these nanoshells seek out their cancerous targets, then applying near-infrared light. In laboratory cultures, the heat generated by the light-absorbing nanoshells can successfully killed breast cancer tumor cells while leaving neighboring cells intact.

A nanometer is a billionth of a meter. It's difficult to imagine anything so small, but think of something only 1/80,000 the width of a human hair. Ten hydrogen atoms could be laid side-by-side in a single nanometer.
GenNxeix minuscule molecule that will be used to detect breast cancer is a quantum dot. Quantum dots are tiny crystals that glow when they are stimulated by ultraviolet light. The wavelength, or color, of the light depends on the size of the crystal. Latex beads filled with these crystals can be designed to bind to specific DNA sequences.

GenNxeix scientists refer to these methods as the top-down approach and the bottom-up approach. The top-down approach involves molding or etching materials into smaller components. This approach has traditionally been used in making parts for computers and electronics. The bottom-up approach involves assembling structures atom-by-atom or molecule-by-molecule, and may prove useful in manufacturing devices used in medicine. Get ready breast cancer science and information technology has breast cancer in the cross hairs

Hybrid GenNxeix Genomics Science Black Tie Ball

HOUSTON, Jan 5/PRNewswire/ — Hybrid Medical is one of the leading supporters of Genomics Science Black Tie Ball to take place April 14 at the Hotel ZA ZA in Houston. Proceeds from the event will support Houston Symphony and American Cancer Soceity, to initiate the development and deployment of promising new Genomics Science and therapies to improve and save patient lives. The celebrity chairperson of The Genomics Science Black Tie Ball is Congress Women Shelia Jackson Lee.
“As a Biotech Engineering company, Hybrid Medical is honored to support The Genomics Science Black Tie Ball ,” says Robert Graham, Executive Vice President of Hybrid Medical North America. “It is only through the medical community and philanthropic outreach that we can complete our mission, which is putting into the hands of healthcare professionals the tools they need to treat breast cancer and to improve, prolong and save patient lives.”

The first and only freestanding Genomics Biotech Engineering center of its kind in Houston, The Hybrid Medical GenNxeix, is hosting the event, as well as serving as a major sponsor Lilly.

“Genomics Science Black Tie Ball was put together with the same principles for why we started Hybrid Medical on the most humanistic level,” says Rose Conrad., the Center’s Founder and CEO. “It is about giving back to people and the community, and bringing genomics cancer care to the next level. It is in harmony with Hybrid Medical’s philosophy, which emphasizes caring for the whole person, not just treating their disease. The most fundamental understanding of the preciousness of life is what has driven us to pursue our dream to help people with cancer–to help them live fuller lives while under our care and ideally once their disease is defeated.”

Houston Press

PERFORMANCES